
Section 1: 8-K (8-K)

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, DC 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported)

February 27, 2018

INOGEN, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-36309
(Commission File Number)

33-0989359
(IRS Employer
Identification No.)

**326 Bollay Drive
Goleta, California 93117**
(Address of principal executive offices, including zip code)

(805) 562-0500
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On February 27, 2018, Inogen, Inc. issued a press release reporting its financial results for the fourth quarter and full year ended December 31, 2017. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

| Exhibit | Description |
|----------------|--------------------|
|----------------|--------------------|

| | |
|------|---|
| 99.1 | Press Release, dated February 27, 2018. |
|------|---|

EXHIBIT INDEX

**Exhibit
No.**

Description

99.1 [Press Release, dated February 27, 2018.](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INOGEN, INC.

Date: February 27, 2018

By: /s/Alison Bauerlein

Alison Bauerlein

Executive Vice President, Finance,

Chief Financial Officer, Secretary and Treasurer

[\(Back To Top\)](#)

Section 2: EX-99.1 (EX-99.1)

Exhibit 99.1

NewsRelease



FOR IMMEDIATE RELEASE

Inogen Announces Fourth Quarter and Full Year 2017 Financial Results and Updates 2018 Guidance

- *Q4 2017 Sales Revenue up 37.0% Over the Same Period in 2016* -
- *Record Revenue for Full Year 2017* -
- *Raises 2018 Guidance* -

Goleta, California, February 27, 2018 — Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three-month and twelve-month periods ended December 31, 2017.

Fourth Quarter 2017 Highlights

- Total revenue of \$63.8 million, up 25.4% over the same period in 2016
 - Sales revenue of \$58.4 million, up 37.0% over the same period in 2016
 - Rental revenue of \$5.4 million, down 34.1% from the same period in 2016
- GAAP net loss of \$0.6 million, reflecting a \$5.9 million decrease from the same period in 2016
- Non-GAAP net income of \$7.0 million, reflecting a 32.5% increase over the same period in 2016 and a 10.9% return on revenue (see accompanying table for reconciliation of GAAP and non-GAAP measures)
- Adjusted EBITDA of \$11.6 million, representing 5.8% growth over the same period in 2016 and an 18.1% return on revenue (see accompanying table for reconciliation of GAAP and non-GAAP measures)
- Total units sold were 34,000, an increase of 10,700, or 45.9%, over the same period in 2016

Full Year 2017 Highlights

- Record total revenue of \$249.4 million, up 23.0% versus 2016
 - Record sales revenue of \$225.5 million, up 34.1% versus 2016
 - Rental revenue of \$23.9 million, down 30.9% versus 2016
- GAAP net income of \$21.0 million, up 2.4% versus 2016
- Record non-GAAP net income of \$28.6 million, reflecting a 39.3% increase versus 2016 and an 11.5% return on revenue
- Record Adjusted EBITDA of \$50.8 million, representing a 17.2% increase versus 2016 and a 20.4% return on revenue
- Record units sold of 128,000, an increase of 36,000, or 39.1%, versus 2016
- 263 inside direct-to-consumer sales representatives as of December 31, 2017, an increase of 86 or 48.6% versus December 31, 2016

“The fourth quarter of 2017 was another successful quarter for us, driven by record sales in our domestic direct-to-consumer channel and strong sales in our domestic business-to-business channel,” said Chief Executive Officer, Scott Wilkinson. “We are executing on our strategic

initiatives and remain focused on increasing adoption of our best-in-class oxygen product offerings across all of our sales channels. We believe we should see strong sales growth in 2018 as portable oxygen concentrator penetration increases worldwide. In the fourth quarter of 2017, we continued hiring in our Cleveland facility primarily to expand our direct-to-consumer sales team. In support of our European customers, we began production of our Inogen One G3 concentrators with our new Czech Republic-based contract manufacturing partner, Foxconn.”

Fourth Quarter 2017 Financial Results

Total revenue for the three months ended December 31, 2017 rose 25.4% to \$63.8 million from \$50.9 million in the same period in 2016. Direct-to-consumer sales rose 57.5% over the same period in 2016, ahead of our expectations and primarily due to an increase in the number of sales representatives, marketing expenditures, and sales representative productivity. Domestic business-to-business sales also exceeded our expectations and grew 46.1% over the same period in 2016, primarily driven by continued strong demand from our private label partner and traditional home medical equipment providers. International business-to-business sales in the fourth quarter of 2017 declined 0.8% from the comparative period in 2016, primarily due to no major European tenders being awarded to our provider partners in the fourth quarter of 2017. Additionally, the fourth quarter of 2016 included sizeable unit orders from South Korea that did not repeat in the fourth quarter of 2017, creating a difficult comparable. Sales in Europe represented 84.3% of international sales in the fourth quarter of 2017, up from 83.3% in the fourth quarter of 2016. Rental revenue in the fourth quarter of 2017 was \$5.4 million compared to \$8.2 million in the fourth quarter of 2016, representing a decline of 34.1% from the same period in the prior year, primarily due to the \$2.0 million rental benefit recorded in the fourth quarter of 2016 associated with the 21st Century Cures Act (Cures Act), which increased reimbursement rates retrospectively for some Medicare beneficiaries, and our continued focus on direct-to-consumer sales versus rentals. Rental revenue declined to 8.5% of total revenue in the fourth quarter of 2017 from 16.2% of total revenue in the fourth quarter of 2016.

Total gross margin was 48.2% in the fourth quarter of 2017 versus 48.5% in the comparative period in 2016. The decrease in total gross margin was primarily due to the \$2.0 million Cures Act benefit recorded in the fourth quarter of 2016, which contributed 2.1% to total gross margin in the fourth quarter of 2016. Sales gross margin was 50.5% in the fourth quarter of 2017 versus 49.9% in the fourth quarter of 2016. The sales gross margin percentage improvement was primarily attributable to an increased sales mix towards direct-to-consumer sales and lower cost of goods sold per unit, mostly due to lower materials costs, partially offset by decreased average selling prices. Rental gross margin was 23.2% in the fourth quarter of 2017 versus 41.4% in the fourth quarter of 2016. The decrease in rental gross margin was primarily due to the \$2.0 million Cures Act benefit recorded in the fourth quarter of 2016, which contributed 19.2% to rental gross margin in the fourth quarter of 2016.

Total operating expense increased to \$25.6 million, or 40.1% of revenue, in the fourth quarter of 2017 versus \$18.5 million, or 36.4% of revenue, in the fourth quarter of 2016 as the Company continued to make investments it expects will increase future revenue growth.

Operating expense included research and development expense of \$1.4 million in the fourth quarter of 2017, which was up slightly from the \$1.2 million recorded in the comparative period in 2016, primarily due to increased product development expenses. Sales and marketing expense increased to \$15.2 million in the fourth quarter of 2017 versus \$9.3 million in the comparative period in 2016, primarily due to increased advertising expense and increased personnel-related expenses due to salesforce additions. General and administrative expense increased to \$9.0

million in the fourth quarter of 2017 versus \$8.0 million in the comparative period in 2016, primarily due to increased personnel-related expenses.

In the fourth quarter of 2017, Inogen's provision for income taxes totaled \$6.4 million, representing an effective tax rate of 110.5%. In the fourth quarter of 2016, Inogen's provision for income taxes totaled \$0.6 million, representing an effective tax rate of 9.8%. As a result of the Tax Cuts and Jobs Act (TCJA) enacted on December 22, 2017, Inogen reported a \$7.6 million non-cash income tax provision expense associated with the revaluation of the deferred tax asset. Our effective tax rate in the fourth quarter of 2017 also included a \$3.5 million decrease in provision for income taxes related to excess tax benefits recognized from stock-based compensation compared to \$1.7 million in the fourth quarter of 2016. Excluding both the deferred tax asset revaluation expense and the stock-based compensation benefit, Inogen's non-GAAP effective tax rate in the fourth quarter of 2017 was 40.0% versus 39.7% in the fourth quarter of 2016.

As a result of the TCJA, Inogen reported a GAAP net loss of \$0.6 million in the fourth quarter of 2017, primarily due to the \$7.6 million non-cash income tax provision expense associated with the revaluation of the Company's noncurrent deferred tax asset. Non-GAAP net income for the fourth quarter of 2017 increased 32.5% to \$7.0 million from \$5.3 million in the fourth quarter of 2016.

Adjusted EBITDA for the three months ended December 31, 2017 rose 5.8% to \$11.6 million, or 18.1% of revenue, from \$10.9 million, or 21.5% of revenue, in the fourth quarter of 2016.

Cash, cash equivalents, and marketable securities were \$173.9 million as of December 31, 2017 compared to \$163.1 million as of September 30, 2017, an increase of \$10.9 million in the fourth quarter of 2017.

Financial Outlook for 2018

Inogen is increasing its full year 2018 total revenue guidance range to \$298 to \$308 million, up from \$295 to \$305 million, representing growth of 19.5% to 23.5% versus 2017 full year results. The Company expects direct-to-consumer sales to be its fastest growing channel, domestic business-to-business sales to have a solid growth rate, and international business-to-business sales to have a modest growth rate, where the strategy will continue to be heavily focused on the European markets. Inogen expects rental revenue to be relatively flat in 2018 compared to 2017 as the Company continues to focus on sales versus rentals.

Further, the Company is also increasing its full year 2018 GAAP net income and non-GAAP net income guidance range to \$36 to \$39 million, up from \$31 to \$35 million, representing growth of 71.4% to 85.7% compared to 2017 GAAP net income of \$21.0 million and growth of 26.0% to 36.5% compared to 2017 non-GAAP net income of \$28.6 million. The Company estimates that the decrease in provision for income taxes related to excess tax benefits recognized from stock-based compensation will lead to a decrease in provision for income taxes of approximately \$8.0 million in 2018 based on forecasted stock activity, which would lower its effective tax rate as compared to the U.S. statutory rate. Excluding the \$8.0 million decrease in provision for income taxes expected in 2018, the Company expects an effective tax rate of approximately 25%, down from its previous estimate of 37% due to the TCJA. The Company expects its effective tax rate including stock compensation deductions to vary quarter-to-quarter depending on the amount of pre-tax net income and on the timing and size of stock option exercises.

Inogen is maintaining its guidance range for full year 2018 Adjusted EBITDA of \$60 to \$64 million, representing 18.0% to 25.9% growth compared to 2017 results.

Inogen also expects net positive cash flow for 2018 with no additional equity capital required to meet its current operating plan.

Conference Call

Individuals interested in listening to the conference call today at 1:30pm PT/4:30pm ET may do so by dialing (855) 238-8123 for domestic callers or (412) 317-5217 for international callers. Please reference Inogen (INGN) to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen's website at: <http://investor.inogen.com/>.

A replay of the call will be available beginning February 27, 2018 at 3:30pm PT/6:30pm ET through 3:30pm PT/6:30pm ET on March 6, 2018. To access the replay, dial (877) 344-7529 or (412) 317-0088 and reference Access Code: 10116324. The webcast will also be available on Inogen's website for one year following the completion of the call.

Inogen has used, and intends to continue to use, its Investor Relations website, <http://investor.inogen.com/>, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit <http://investor.inogen.com/>.

About Inogen

Inogen is innovation in oxygen therapy. We are a medical technology company that develops, manufactures and markets innovative oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

For more information, please visit www.inogen.com.

Cautionary Note Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding anticipated growth opportunities; expectations for all revenue channels for full year 2018; the expected impact of the decrease in provision for income taxes related to excess tax benefits recognized from stock-based compensation for full year 2018; and financial guidance for 2018, including revenue, GAAP net income, Adjusted EBITDA, non-GAAP net income, net cash flow, effective tax rates, and the need for equity financing. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks arising from the possibility that Inogen will not realize anticipated revenue; the impact of reduced reimbursement rates, including private payor reductions and reductions in connection with competitive bidding and the Center for Medicare and Medicaid Services (CMS) rules; the possible loss of key employees, customers, or suppliers; and intellectual property risks if Inogen is unable to secure and maintain patent or other intellectual property protection for the intellectual property used in its products. In addition, Inogen's business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks,

uncertainties, and other information affecting Inogen's business operating results are contained in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 and in its other filings with the Securities and Exchange Commission. Additional information will also be set forth in Inogen's Annual Report on Form 10-K for the year ended December 31, 2017 to be filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.

Use of Non-GAAP Financial Measures

Inogen has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three and twelve months ended December 31, 2017 and December 31, 2016. Management believes that non-GAAP financial measures, taken in conjunction with U.S. GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of Inogen's core operating results. Management uses non-GAAP measures to compare Inogen's performance relative to forecasts and strategic plans, to benchmark Inogen's performance externally against competitors, and for certain compensation decisions. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Inogen's operating results as reported under U.S. GAAP. Inogen encourages investors to carefully consider its results under U.S. GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between U.S. GAAP and non-GAAP results are presented in the accompanying table of this release. For future periods, Inogen is unable to provide a reconciliation of non-GAAP measures without unreasonable effort as a result of the uncertainty regarding, and the potential variability of, the amounts of interest income, interest expense, depreciation and amortization, stock-based compensation, provisions for income taxes, and certain other infrequently occurring items, such as acquisition related costs, that may be incurred in the future.

Investor Relations Contact:

Matt Bacso, CFA
mbacso@inogen.net
805-879-8205

Media Contact:

Byron Myers
805-562-0503

-- Financial Tables Follow --

Consolidated Balance Sheets
(unaudited)
(amounts in thousands)

| | December 31, | |
|---|-------------------|-------------------|
| | 2017 | 2016 |
| Assets | | |
| Current assets | | |
| Cash and cash equivalents | \$ 142,953 | \$ 92,851 |
| Marketable securities | 30,991 | 21,033 |
| Accounts receivable, net | 31,444 | 30,828 |
| Inventories, net | 18,842 | 14,343 |
| Deferred cost of revenue | 361 | 398 |
| Income tax receivable | 1,313 | 433 |
| Prepaid expenses and other current assets | 2,584 | 1,659 |
| Total current assets | 228,488 | 161,545 |
| Property and equipment, net | 20,103 | 25,199 |
| Goodwill | 2,363 | — |
| Intangible assets, net | 4,717 | 241 |
| Deferred tax asset - noncurrent | 18,636 | 26,654 |
| Other assets | 765 | 410 |
| Total assets | \$ 275,072 | \$ 214,049 |
| Liabilities and stockholders' equity | | |
| Current liabilities | | |
| Accounts payable and accrued expenses | \$ 20,626 | \$ 12,795 |
| Accrued payroll | 6,877 | 6,123 |
| Warranty reserve - current | 2,505 | 1,688 |
| Deferred revenue - current | 3,533 | 2,239 |
| Income tax payable | 345 | — |
| Total current liabilities | 33,886 | 22,845 |
| Warranty reserve - noncurrent | 3,666 | 1,792 |
| Deferred revenue - noncurrent | 9,402 | 7,042 |
| Deferred tax liability - noncurrent | 348 | — |
| Other noncurrent liabilities | 729 | 282 |
| Total liabilities | 48,031 | 31,961 |
| Stockholders' equity | | |
| Common stock | 21 | 20 |
| Additional paid-in capital | 218,109 | 194,466 |
| Retained earnings (accumulated deficit) | 8,639 | (12,363) |
| Accumulated other comprehensive income (loss) | 272 | (35) |
| Total stockholders' equity | 227,041 | 182,088 |
| Total liabilities and stockholders' equity | \$ 275,072 | \$ 214,049 |

Consolidated Statements of Comprehensive Income
(unaudited)
(amounts in thousands, except share and per share amounts)

| | Three months ended | | Twelve months ended | |
|---|--------------------|-----------------|---------------------|------------------|
| | December 31, | | December 31, | |
| | 2017 | 2016 | 2017 | 2016 |
| Revenue | | | | |
| Sales revenue | \$ 58,351 | \$ 42,604 | \$ 225,492 | \$ 168,170 |
| Rental revenue | 5,436 | 8,247 | 23,946 | 34,659 |
| Total revenue | <u>63,787</u> | <u>50,851</u> | <u>249,438</u> | <u>202,829</u> |
| Cost of revenue | | | | |
| Cost of sales revenue | 28,856 | 21,330 | 110,163 | 85,154 |
| Cost of rental revenue, including depreciation of \$2,258 and \$2,696 for the three months ended and \$9,835 and \$11,429 for the twelve months ended, respectively | 4,175 | 4,833 | 18,038 | 20,365 |
| Total cost of revenue | <u>33,031</u> | <u>26,163</u> | <u>128,201</u> | <u>105,519</u> |
| Gross profit | <u>30,756</u> | <u>24,688</u> | <u>121,237</u> | <u>97,310</u> |
| Operating expense | | | | |
| Research and development | 1,369 | 1,216 | 5,313 | 5,113 |
| Sales and marketing | 15,189 | 9,320 | 50,758 | 37,540 |
| General and administrative | 9,008 | 7,981 | 37,576 | 31,793 |
| Total operating expense | <u>25,566</u> | <u>18,517</u> | <u>93,647</u> | <u>74,446</u> |
| Income from operations | <u>5,190</u> | <u>6,171</u> | <u>27,590</u> | <u>22,864</u> |
| Other income (expense) | | | | |
| Interest expense | — | — | — | (6) |
| Interest income | 297 | 70 | 765 | 196 |
| Other income (expense) | 307 | (407) | 1,301 | (329) |
| Total other income (expense), net | <u>604</u> | <u>(337)</u> | <u>2,066</u> | <u>(139)</u> |
| Income before provision for income taxes | <u>5,794</u> | <u>5,834</u> | <u>29,656</u> | <u>22,725</u> |
| Provision for income taxes | <u>6,400</u> | <u>574</u> | <u>8,654</u> | <u>2,206</u> |
| Net income (loss) | <u>\$ (606)</u> | <u>\$ 5,260</u> | <u>\$ 21,002</u> | <u>\$ 20,519</u> |
| Other comprehensive income (loss), net of tax | | | | |
| Change in foreign currency translation adjustment | 51 | — | 363 | — |
| Change in net unrealized gains (losses) on foreign currency hedging | (125) | 79 | (567) | 55 |
| Less: reclassification adjustment for net (gains) losses included in net income | 149 | (45) | 446 | 6 |
| Total net change in unrealized gains (losses) on foreign currency hedging | 24 | 34 | (121) | 61 |
| Change in net unrealized gains (losses) on available-for-sale investments | (6) | (75) | 65 | (59) |
| Total other comprehensive income (loss), net of tax | <u>69</u> | <u>(41)</u> | <u>307</u> | <u>2</u> |
| Comprehensive income (loss) | <u>\$ (537)</u> | <u>\$ 5,219</u> | <u>\$ 21,309</u> | <u>\$ 20,521</u> |
| Basic net income (loss) per share attributable to common stockholders ⁽¹⁾ | <u>\$ (0.03)</u> | <u>\$ 0.26</u> | <u>\$ 1.02</u> | <u>\$ 1.02</u> |
| Diluted net income (loss) per share attributable to common stockholders ⁽¹⁾ | <u>\$ (0.03)</u> | <u>\$ 0.25</u> | <u>\$ 0.96</u> | <u>\$ 0.97</u> |
| Weighted-average number of shares used in calculating net income (loss) per share attributable to common stockholders: | | | | |
| Basic common shares | 20,869,589 | 20,310,857 | 20,683,807 | 20,067,152 |
| Diluted common shares | 22,167,358 | 21,362,513 | 21,897,988 | 21,095,867 |

⁽¹⁾ Reconciliations of net income (loss) attributable to common stockholders basic and diluted can be found in Inogen's Annual Report on Form 10-K to be filed with the Securities and Exchange Commission.

Supplemental Financial Information

(unaudited)

(in thousands, except units and patients)

| | Three months ended | | Twelve months ended | |
|--|--------------------|------------------|---------------------|-------------------|
| | December 31, | | December 31, | |
| | 2017 | 2016 | 2017 | 2016 |
| Revenue by region and category | | | | |
| Business-to-business domestic sales | \$ 21,856 | \$ 14,958 | \$ 83,390 | \$ 56,605 |
| Business-to-business international sales | 11,991 | 12,091 | 55,519 | 50,106 |
| Direct-to-consumer domestic sales | 24,504 | 15,555 | 86,583 | 61,459 |
| Direct-to-consumer domestic rentals | 5,436 | 8,247 | 23,946 | 34,659 |
| Total revenue | \$ 63,787 | \$ 50,851 | \$ 249,438 | \$ 202,829 |
| Additional financial measures | | | | |
| Units sold | 34,000 | 23,300 | 128,000 | 92,000 |
| Net rental patients as of period-end | 30,700 | 33,300 | 30,700 | 33,300 |

Reconciliation of U.S. GAAP to Other Non-GAAP Financial Measures

(unaudited)

(in thousands)

| | Three months ended | | Twelve months ended | |
|--|--------------------|------------------|---------------------|------------------|
| | December 31, | | December 31, | |
| | 2017 | 2016 | 2017 | 2016 |
| Non-GAAP EBITDA and Adjusted EBITDA | | | | |
| Net income (loss) | \$ (606) | \$ 5,260 | \$ 21,002 | \$ 20,519 |
| Non-GAAP adjustments: | | | | |
| Interest expense | — | — | — | 6 |
| Interest income | (297) | (70) | (765) | (196) |
| Provision for income taxes | 6,400 | 574 | 8,654 | 2,206 |
| Depreciation and amortization | 3,045 | 3,268 | 12,302 | 13,558 |
| EBITDA (non-GAAP) | 8,542 | 9,032 | 41,193 | 36,093 |
| Stock-based compensation | 3,010 | 1,890 | 9,640 | 7,294 |
| Adjusted EBITDA (non-GAAP) | \$ 11,552 | \$ 10,922 | \$ 50,833 | \$ 43,387 |

| | Three months ended | | Twelve months ended | |
|-------------------------------------|--------------------|-----------------|---------------------|------------------|
| | December 31, | | December 31, | |
| | 2017 | 2016 | 2017 | 2016 |
| Non-GAAP net income | | | | |
| Net income (loss) | \$ (606) | \$ 5,260 | \$ 21,002 | \$ 20,519 |
| Non-GAAP adjustments: | | | | |
| 2017 U.S. tax reform ⁽¹⁾ | 7,578 | — | 7,578 | — |
| Non-GAAP net income | \$ 6,972 | \$ 5,260 | \$ 28,580 | \$ 20,519 |

| | Three months ended | | Twelve months ended | |
|--|--------------------|------------------|---------------------|------------------|
| | December 31, | | December 31, | |
| | 2017 | 2016 | 2017 | 2016 |
| Non-GAAP operating expense | | | | |
| Operating expense | \$ 25,566 | \$ 18,517 | \$ 93,647 | \$ 74,446 |
| Non-GAAP adjustments: | | | | |
| Litigation settlement benefit (expense), net ⁽²⁾ | (100) | 110 | (576) | 202 |
| Operating expense, excluding certain operating expenses (non-GAAP) | \$ 25,466 | \$ 18,627 | \$ 93,071 | \$ 74,648 |

| | Three months ended | | Twelve months ended | |
|--|--------------------|------------------|---------------------|------------------|
| | December 31, | | December 31, | |
| | 2017 | 2016 | 2017 | 2016 |
| Non-GAAP - sales, general & administrative (SG&A) expense | | | | |
| SG&A expense | \$ 24,197 | \$ 17,301 | \$ 88,334 | \$ 69,333 |
| Non-GAAP adjustments: | | | | |
| Litigation settlement benefit (expense), net ⁽²⁾ | (100) | 110 | (576) | 202 |
| SG&A expense, excluding certain operating expenses (non-GAAP) | \$ 24,097 | \$ 17,411 | \$ 87,758 | \$ 69,535 |

⁽¹⁾ On December 22, 2017, the Tax Cuts and Jobs Act (TCJA) was enacted into law, which significantly changes existing U.S. tax law and includes numerous provisions that affect the Company. During the fourth quarter of 2017, the Company recorded an estimated one-time net charge due to the impact of changes in the tax rate, primarily on deferred tax assets.

⁽²⁾ Amounts in 2017 consist of a patent litigation settlement expense, net of a benefit, in the third and fourth quarters. Amounts in 2016 consist of a patent litigation settlement benefit partially offset by a litigation expense associated with a labor law class-action lawsuit that was accrued in the first quarter of 2016 and paid in the fourth quarter of 2016.

| Non-GAAP provision for income taxes and effective tax rate | Three months ended | | Twelve months ended | |
|---|---------------------------|-------------|----------------------------|-------------|
| | December 31, | | December 31, | |
| | 2017 | 2016 | 2017 | 2016 |
| Income before provision for income taxes | \$ 5,794 | \$ 5,834 | \$ 29,656 | \$ 22,725 |
| Provision for income taxes | 6,400 | 574 | 8,654 | 2,206 |
| Effective tax rate | 110.5% | 9.8% | 29.2% | 9.7% |
| Provision for income taxes | \$ 6,400 | \$ 574 | \$ 8,654 | \$ 2,206 |
| Non-GAAP adjustments: | | | | |
| Excess tax benefits from stock-based compensation | 3,495 | 1,745 | 9,936 | 6,042 |
| 2017 U.S. tax reform ⁽¹⁾ | (7,578) | — | (7,578) | — |
| Provision for income taxes (non-GAAP) | \$ 2,317 | \$ 2,319 | \$ 11,012 | \$ 8,248 |
| Income before provision for income taxes | \$ 5,794 | \$ 5,834 | \$ 29,656 | \$ 22,725 |
| Provision for income taxes (non-GAAP) | 2,317 | 2,319 | 11,012 | 8,248 |
| Effective tax rate (non-GAAP) | 40.0% | 39.7% | 37.1% | 36.3% |

⁽¹⁾ On December 22, 2017, the Tax Cuts and Jobs Act (TCJA) was enacted into law, which significantly changes existing U.S. tax law and includes numerous provisions that affect the Company. During the fourth quarter of 2017, the Company recorded an estimated one-time net charge due to the impact of changes in the tax rate, primarily on deferred tax assets.

[\(Back To Top\)](#)